Interventional cardiology news to note

A new tool that predicts mortality within 30 days of transcatheter aortic valve replacement had only modest predictive power, even after accounting for patient frailty. The model was derived from the UK-TAVI Registry. (Heart)

Percutaneous septal reduction therapy for hypertrophic obstructive cardiomyopathy can be accomplished with a non-alcohol agent, ethylene-vinyl alcohol copolymer. Use of this agent was associated with reduced interventricular septum thickness and left ventricular outflow tract gradient, investigators reported in Catheterization and Cardiovascular Interventions.

Patients with heart failure had the same procedural characteristics and outcomes after catheter ablation for Afib whether they had preserved or reduced ejection fraction, researchers reported in HeartRhythm. Freedom from recurrent atrial arrhythmia was just over 30% in both groups at 12 months.

Pretreating large-vessel occlusions with IV thrombolysis resulted in successful reperfusion 11% of the time even before mechanical thrombectomy, according to a meta-analysis. (Stroke)

Elective endovascular repair is gaining traction over open repair for popliteal artery aneurysms, according to a single-center Swedish study. The downside with endovascular repair may be increased odds of amputation, however. (Vascular and Endovascular Surgery)

Patients presenting with acute MI complicated by cardiogenic shock were at higher risk of mortality in the year after revascularization if they had a chronic total occlusion in a non-infarct-related coronary artery. These patients were also more likely to require defibrillation for ventricular arrhythmias in the first 30 days, according to a substudy of the IABP-SHOCK II trial. (EuroIntervention)

Accessibility Statement

At MedPage Today, we are committed to ensuring that individuals with disabilities can access all of the content offered by MedPage Today through our website and other properties. If you are having trouble accessing www.medpagetoday.com, MedPageToday's mobile apps, please email legal@ziffdavis.com for assistance. Please put "ADA Inquiry" in the subject line of your email.